Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of bemnifosbuvir in high-risk outpatients with COVID-19
jRCT2071240070Phase 3Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Nov 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Bemnifosbuvir with Placebo (2 arms). Primary endpoint: Proportion of subjects hospitalized for any cause or died due to any cause. Started Nov 2022; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071240070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240070.